BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/30/2024 9:47:23 AM | Browse: 115 | Download: 291
 |
Received |
|
2024-06-29 01:48 |
|
Peer-Review Started |
|
2024-06-29 01:48 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2024-09-29 13:01 |
|
Revised |
|
2024-10-11 04:17 |
|
Second Decision |
|
2024-10-24 02:54 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2024-12-02 10:27 |
|
Articles in Press |
|
2024-12-02 10:27 |
|
Publication Fee Transferred |
|
2024-12-02 13:00 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-12-09 02:13 |
|
Publish the Manuscript Online |
|
2024-12-30 09:47 |
| ISSN |
1948-9358 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Endocrinology & Metabolism |
| Manuscript Type |
Prospective Study |
| Article Title |
Efficacy of sodium−glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists on proteinuria and weight in a diabetes cohort
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Di-Fei Lu, Rui Zheng, Ang Li and Jun-Qing Zhang |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Jun-Qing Zhang, MD, PhD, Department of Endocrinology, Peking University First Hospital, No. 8 Xishiku Street, Xicheng District, Beijing 100034, China. junqing.zhang@pkufh.com |
| Key Words |
Type 2 diabetes; Chronic kidney disease; Body weight; Sodium-glucose cotransporter-2 inhibitors; Glucagon-like peptide-1 receptor agonists |
| Core Tip |
In this study, a cohort of 5482 patients with type 2 diabetes were enrolled and followed up for at least 6 months. After propensity score matching, patients who received GLP-1RA or SGLT2i were compared with those who did not receive either treatment. Patients with increased BMIs were predisposed to treatment with GLP-1RAs, and those with higher UACRs were more likely to be treated with SGLT2is. Patients on SGLT2i or GLP-1RAs showed significant weight loss, a decreasing trend in UACR and comparable glucose-lowering effects compared with patients who received glucose-lowering drugs other than SGLT2i or GLP-1RA in real-world settings. |
| Publish Date |
2024-12-30 09:47 |
| Citation |
<p>Lu DF, Zheng R, Li A, Zhang JQ. Efficacy of sodium−glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists on proteinuria and weight in a diabetes cohort. <i>World J Diabetes</i> 2025; 16(2): 98552</p> |
| URL |
https://www.wjgnet.com/1948-9358/full/v16/i2/98552.htm |
| DOI |
https://dx.doi.org/10.4239/wjd.v16.i2.98552 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
